<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02661815</url>
  </required_header>
  <id_info>
    <org_study_id>15-483</org_study_id>
    <nct_id>NCT02661815</nct_id>
  </id_info>
  <brief_title>A Phase 1b Study of Paclitaxel And Ricolinostat For The Treatment Of Gynecological Cancer</brief_title>
  <official_title>A Phase 1b Study of Weekly Paclitaxel And Oral Ricolinostat For The Treatment Of Recurrent Platinum Resistant Ovarian, Primary Peritoneal, Or Fallopian Tube Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dana-Farber Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Celgene Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Dana-Farber Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Participants with Ovarian, Fallopian Tube, or Peritoneal Cancer that has recurred within 12&#xD;
      months of prior treatment that includes Platinum Chemotherapy are invited to take part in&#xD;
      this study. This research study is studying a combination of a new chemotherapy drug called&#xD;
      Ricolinostat together with the chemotherapy Paclitaxel and a drug called Bevacizumab as a&#xD;
      possible treatment for this diagnosis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This research study is a Phase I clinical trial, which tests the safety of an investigational&#xD;
      intervention and also tries to define the appropriate dose of the investigational&#xD;
      intervention to use for further studies.&#xD;
&#xD;
      The FDA (the U.S. Food and Drug Administration) has not approved Ricolinostat as a treatment&#xD;
      for any disease. The FDA has approved Paclitaxel as a treatment option for Ovarian, Fallopian&#xD;
      Tube, or Peritoneal Cancer . The FDA has approved Bevacizumab in combination with&#xD;
      chemotherapy as a treatment option for Ovarian, Fallopian Tube, or Peritoneal Cancer .&#xD;
&#xD;
      In this study, we are hoping to learn what is the highest dose of Ricolinostat that can be&#xD;
      given safely together with Paclitaxel on a weekly basis or with Paclitaxel on a weekly basis&#xD;
      and Bevacizumab every other week. Ricolinostat is a drug that stops cancer from growing by&#xD;
      blocking the action of a protein called HDAC.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Company decided not to move forward with further accrual.&#xD;
  </why_stopped>
  <start_date type="Actual">June 15, 2016</start_date>
  <completion_date type="Actual">July 28, 2017</completion_date>
  <primary_completion_date type="Actual">June 28, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Analysis Report on the MTD In The Dose Escalation Portion Of The Study</measure>
    <time_frame>2 years</time_frame>
    <description>Not assessed, the MTD was not reached as the study was terminated.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Best Overall Response Measured From, Start Of Treatment To The End</measure>
    <time_frame>13 months</time_frame>
    <description>This is now the primary outcome measure as the study was terminated prematurely.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Peripheral Neurotoxicity Assessed Using TNS by Measuring 5 Categories</measure>
    <time_frame>0 years</time_frame>
    <description>No assessed TNS would only be assessed during escalation which we did not reach as the study was terminated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration Of Overall Response, Measured From The Time Measurement Criteria Are Met For PR or CR Until The First Date Recurrent Or Progressive Disease Is Objectively Documented.</measure>
    <time_frame>2 years</time_frame>
    <description>Not assessed, study was terminated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival (PFS)</measure>
    <time_frame>2 years</time_frame>
    <description>No assessed, study was terminated.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Ovarian Cancer</condition>
  <condition>Fallopian Tube Cancer</condition>
  <condition>Primary Peritoneal Carcinoma</condition>
  <arm_group>
    <arm_group_label>Phase 1 Expansion Cohort A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Paclitaxel 80mg/m2 weekly days 1, 8, and 15 of a 28-day cycle Ricolinostat dosing as identified as the RP2D combination dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 1 Expansion Cohort B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Paclitaxel 70mg/m2 weekly days 1, 8, and 15 of a 28-day cycle Ricolinostat dosing as identified as the RP2D combination dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 1 Expansion Cohort C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Paclitaxel 80mg/m2 weekly days 1, 8, and 15 of a 28-day cycle Bevacizumab 10mg/kg days 1 and 15 of a 28-day cycle Ricolinostat dosing as identified as the RP2D combination dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 1 Escalation Cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ricolinostat with weekly paclitaxel dosed at 80 mg/m2 per week (3 out of 4 weeks).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>Please see arm/group description.</description>
    <arm_group_label>Phase 1 Escalation Cohort</arm_group_label>
    <arm_group_label>Phase 1 Expansion Cohort A</arm_group_label>
    <arm_group_label>Phase 1 Expansion Cohort B</arm_group_label>
    <arm_group_label>Phase 1 Expansion Cohort C</arm_group_label>
    <other_name>Taxol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ricolinostat</intervention_name>
    <description>Please see arm/group description.</description>
    <arm_group_label>Phase 1 Escalation Cohort</arm_group_label>
    <arm_group_label>Phase 1 Expansion Cohort A</arm_group_label>
    <arm_group_label>Phase 1 Expansion Cohort B</arm_group_label>
    <arm_group_label>Phase 1 Expansion Cohort C</arm_group_label>
    <other_name>ACY-1215</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>Please see arm/group description.</description>
    <arm_group_label>Phase 1 Expansion Cohort C</arm_group_label>
    <other_name>Avastin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participants must have recurrent or persistent epithelial ovarian, fallopian tube or&#xD;
             primary peritoneal carcinoma, recurrent endometrial cancer, or recurrent cervical&#xD;
             cancer. Histologic documentation of the original primary tumor is required via the&#xD;
             pathology report.&#xD;
&#xD;
          -  Participants must have measurable disease by RECIST 1.1 criteria. See Section 11 for&#xD;
             the evaluation of measurable disease.&#xD;
&#xD;
          -  Participants must have had at least one prior platinum-based chemotherapeutic regimen&#xD;
             for management of primary disease (e.g., a regimen containing carboplatin, cisplatin,&#xD;
             or another organoplatinum compound). This initial treatment may have included&#xD;
             intraperitoneal therapy, consolidation, biologic/targeted (non-cytotoxic) agents&#xD;
             (e.g., bevacizumab) or extended therapy administered after surgical or non-surgical&#xD;
             assessment.&#xD;
&#xD;
        Participants are allowed to receive, but are not required to receive, biologic/targeted&#xD;
        (non-cytotoxic) therapy as part of their primary treatment regimen.&#xD;
&#xD;
          -  Participants must have recurrence within 12 months of their last platinum-containing&#xD;
             regimen.&#xD;
&#xD;
          -  Age 18 years or older&#xD;
&#xD;
          -  ECOG performance status 0 or 1&#xD;
&#xD;
          -  Life expectancy of greater than 16 weeks&#xD;
&#xD;
          -  Participants must have normal organ and marrow function as defined below:&#xD;
&#xD;
               -  Leukocytes ≥3,000/mcL&#xD;
&#xD;
               -  Absolute neutrophil count ≥1,500/mcL&#xD;
&#xD;
               -  Platelets ≥100,000/mcL&#xD;
&#xD;
               -  Total bilirubin within normal institutional limits&#xD;
&#xD;
               -  AST(SGOT)/ALT(SGPT) ≤2.5 × institutional upper limit of normal&#xD;
&#xD;
               -  Creatinine within normal institutional limits OR&#xD;
&#xD;
               -  Creatinine clearance ≥60 mL/min/1.73 m2 for participants with creatinine levels&#xD;
                  above institutional normal.&#xD;
&#xD;
          -  Previous toxicities from previous treatment must have resolved to grade 1 or less&#xD;
&#xD;
          -  For patients in expansion cohort B, stable Grade 2 neuropathy will be allowed.&#xD;
&#xD;
          -  The effects of both paclitaxel and oral ricolinostat on the developing human fetus are&#xD;
             unknown. For this reason, women of child-bearing potential and men must agree to use&#xD;
             adequate contraception (hormonal or barrier method of birth control; abstinence) prior&#xD;
             to study entry and for the duration of study participation. Should a woman become&#xD;
             pregnant or suspect she is pregnant while she or her partner is participating in this&#xD;
             study, she should inform her treating physician immediately.&#xD;
&#xD;
          -  Participants must be able and willing to swallow pills and to absorb oral medications.&#xD;
&#xD;
          -  Ability to understand and the willingness to sign a written informed consent document&#xD;
&#xD;
          -  Participants must be able and willing to follow protocol instructions and schedules.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participants who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for&#xD;
             nitrosoureas or mitomycin C) prior to entering the study or those who have not&#xD;
             recovered from adverse events due to agents administered more than 4 weeks earlier. In&#xD;
             addition, no small molecule kinase inhibitors or any other type of investigational&#xD;
             agent may have been administered within 4 weeks before first dose of study treatment.&#xD;
&#xD;
          -  Participants may not be receiving any other investigational agents for treatment of&#xD;
             their cancer.&#xD;
&#xD;
          -  No hormonal therapy is allowed within 1 week of initiating study treatment.&#xD;
&#xD;
          -  Participants may not have had radiation to &gt;25% of the bone marrow.&#xD;
&#xD;
          -  Prior treatment with a histone deacetylase inhibitor.&#xD;
&#xD;
          -  Prior treatment with weekly paclitaxel for recurrent or persistent disease is not&#xD;
             allowed. Participants may have received weekly paclitaxel as part of treatment for&#xD;
             newly diagnosed cancer, but may not have received it as maintenance therapy following&#xD;
             their initial therapy with platinum and taxane therapy.&#xD;
&#xD;
          -  Participants with known brain metastases should be excluded from this clinical trial&#xD;
             because of their poor prognosis and because they often develop progressive neurologic&#xD;
             dysfunction that would confound the evaluation of neurologic and other adverse events.&#xD;
&#xD;
          -  History of severe allergic reactions attributed to compounds of similar chemical or&#xD;
             biologic composition to either paclitaxel or Ricolinostat. Patients who require&#xD;
             administration of paclitaxel through a desensitization procedure are not eligible for&#xD;
             this study.&#xD;
&#xD;
          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active&#xD;
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac&#xD;
             arrhythmia, or psychiatric illness/social situations that would limit compliance with&#xD;
             study requirements.&#xD;
&#xD;
          -  Patients with chronic viral illnesses such as HIV-positivity and active hepatitis B or&#xD;
             C are ineligible because they are at increased risk of lethal infections when treated&#xD;
             with marrow-suppressive therapy.&#xD;
&#xD;
          -  Any signs, symptoms, and/or radiographic evidence of a complete or partial bowel&#xD;
             obstruction&#xD;
&#xD;
          -  Patients with a history of other invasive malignancies, with the exception of&#xD;
             non-melanoma skin cancer and other specific malignancies as noted below, are excluded&#xD;
             if there is any evidence of other malignancy being present within the last three&#xD;
             years. Patients are also excluded if their previous cancer treatment contraindicates&#xD;
             this protocol therapy.&#xD;
&#xD;
               -  Carcinoma in situ of the breast or cervix&#xD;
&#xD;
               -  Primary endometrial cancer meeting the following conditions: Stage not greater&#xD;
                  than IA, grade 1 or 2, no more than superficial myometrial invasion, without&#xD;
                  vascular or lymphatic invasion; no poorly differentiated subtypes, including&#xD;
                  papillary serous, clear cell, or other FIGO grade 3 lesions.&#xD;
&#xD;
          -  Patients who have received prior chemotherapy for any abdominal or pelvic tumor OTHER&#xD;
             THAN for the treatment of ovarian, fallopian tube, or primary peritoneal cancer within&#xD;
             the last three years are excluded. Patients may have received prior adjuvant&#xD;
             chemotherapy for localized breast cancer, provided that it was completed more than&#xD;
             three years prior to registration, and the patient remains free of recurrent or&#xD;
             metastatic disease.&#xD;
&#xD;
          -  Patients with clinically significant cardiovascular disease. This includes:&#xD;
&#xD;
               -  Uncontrolled hypertension, defined as systolic greater than 140 mm Hg or&#xD;
                  diastolic greater than 90 mm Hg despite antihypertensive medications.&#xD;
&#xD;
               -  Myocardial infarction or unstable angina within 6 months prior to registration.&#xD;
&#xD;
               -  New York Heart Association (NYHA) Class II or greater congestive heart failure.&#xD;
                  (see Appendix III )&#xD;
&#xD;
               -  History of serious ventricular arrhythmia (i.e., ventricular tachycardia or&#xD;
                  ventricular fibrillation) or serious cardiac arrhythmia requiring medication.&#xD;
                  This does not include asymptomatic atrial fibrillation with controlled&#xD;
                  ventricular rate.&#xD;
&#xD;
               -  Any history of congenital long QT syndrome&#xD;
&#xD;
               -  The subject has a corrected QT interval calculated by the Fridericia formula&#xD;
                  (QTcF) &gt;500 ms within 28 days before randomization. Note: if initial QTcF is&#xD;
                  found to be &gt; 500 ms, two additional EKGs separated by at least 3 minutes should&#xD;
                  be performed. If the average of these three consecutive results for QTcF is ≤500&#xD;
                  ms, the subject meets eligibility in this regard.&#xD;
&#xD;
          -  Patients with serious non-healing wound, ulcer, or bone fracture within 28 days before&#xD;
             registration&#xD;
&#xD;
          -  Patients with history of organ transplant.&#xD;
&#xD;
          -  Patients with active bleeding or pathologic conditions that carry high risk of&#xD;
             bleeding, such as known bleeding disorder, coagulopathy, or tumor involving (in&#xD;
             contact with, invading or encasing) major vessels.&#xD;
&#xD;
          -  Gastrointestinal disorders, particularly those with potential risk of perforation or&#xD;
             fistula formation including:&#xD;
&#xD;
               -  Any of the following within 28 days of registration&#xD;
&#xD;
               -  Intra-abdominal tumor/metastases invading GI mucosa&#xD;
&#xD;
               -  Active peptic ulcer disease&#xD;
&#xD;
               -  Inflammatory bowel disease (including ulcerative colitis and Crohn's disease),&#xD;
                  diverticulitis, cholecystitis, symptomatic cholangitis or appendicitis&#xD;
&#xD;
               -  Malabsorption syndrome.&#xD;
&#xD;
               -  Any of the following within 6 months of registration&#xD;
&#xD;
               -  Abdominal fistula&#xD;
&#xD;
               -  Gastrointestinal perforation&#xD;
&#xD;
               -  Bowel obstruction or gastric outlet obstruction&#xD;
&#xD;
               -  Note: Patients requiring drainage gastrostomy (e.g., PEG tube) and/or parenteral&#xD;
                  hydration and/or nutrition are not eligible.&#xD;
&#xD;
               -  Intraabdominal abscess.&#xD;
&#xD;
               -  Note: Complete resolution of an intraabdominal abscess must be confirmed prior to&#xD;
                  registration even if the abscess occurred more than 6 months prior to&#xD;
                  registration.&#xD;
&#xD;
          -  Patients with history or evidence upon physical examination of CNS disease, including&#xD;
             primary brain tumor, seizures which are not controlled with non-enzyme inducing&#xD;
             anticonvulsants, any brain metastases and/or epidural disease, or history of&#xD;
             cerebrovascular accident (CVA, stroke), transient ischemic attack (TIA) or&#xD;
             subarachnoid hemorrhage within six months prior to the first date of study treatment.&#xD;
&#xD;
          -  Major surgery within 3 months of the first dose of study drugs if there were no wound&#xD;
             healing complications or within 6 months of the first dose of study drugs if there&#xD;
             were wound complications.&#xD;
&#xD;
          -  The following are additional exclusion criteria for patients enrolling in Expansion&#xD;
             Cohort C:&#xD;
&#xD;
          -  Uncontrolled blood pressure (&gt;140/90). Patients should have a blood pressure of&#xD;
             ≤140/90 taken by a medical professional within one week of starting on study&#xD;
&#xD;
          -  Proteinuria &gt;2+ on urinalysis&#xD;
&#xD;
          -  Serosal involvement of the bowel that would render the patient at increased risk of&#xD;
             gastrointestinal perforation&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joyce Liu, MD MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dana-Farber Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massacusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>January 20, 2016</study_first_submitted>
  <study_first_submitted_qc>January 20, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 25, 2016</study_first_posted>
  <results_first_submitted>April 16, 2019</results_first_submitted>
  <results_first_submitted_qc>November 7, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">November 8, 2019</results_first_posted>
  <last_update_submitted>November 7, 2019</last_update_submitted>
  <last_update_submitted_qc>November 7, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Dana-Farber Cancer Institute</investigator_affiliation>
    <investigator_full_name>Joyce Liu, MD</investigator_full_name>
    <investigator_title>Joyce Liu, MD, MPH</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fallopian Tube Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Ricolinostat</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 20, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/15/NCT02661815/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patient were recruited in medical clinics from 03/28/2016 to 01/17/2017, the first patient was enrolled on 06/15/2016.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Phase 1 Escalation Cohort</title>
          <description>Ricolinostat with weekly paclitaxel dosed at 80 mg/m2 per week (3 out of 4 weeks).&#xD;
Paclitaxel: Please see arm/group description.&#xD;
Ricolinostat: Please see arm/group description.</description>
        </group>
        <group group_id="P2">
          <title>Phase 1 Expansion Cohort A</title>
          <description>Paclitaxel 80mg/m2 weekly days 1, 8, and 15 of a 28-day cycle Ricolinostat dosing as identified as the RP2D combination dose&#xD;
Paclitaxel: Please see arm/group description.&#xD;
Ricolinostat: Please see arm/group description.</description>
        </group>
        <group group_id="P3">
          <title>Phase 1 Expansion Cohort B</title>
          <description>Paclitaxel 70mg/m2 weekly days 1, 8, and 15 of a 28-day cycle Ricolinostat dosing as identified as the RP2D combination dose&#xD;
Paclitaxel: Please see arm/group description.&#xD;
Ricolinostat: Please see arm/group description.</description>
        </group>
        <group group_id="P4">
          <title>Phase 1 Expansion Cohort C</title>
          <description>Paclitaxel 80mg/m2 weekly days 1, 8, and 15 of a 28-day cycle Bevacizumab 10mg/kg days 1 and 15 of a 28-day cycle Ricolinostat dosing as identified as the RP2D combination dose&#xD;
Paclitaxel: Please see arm/group description.&#xD;
Ricolinostat: Please see arm/group description.&#xD;
Bevacizumab: Please see arm/group description.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Participants were only enrolled to the escalation cohort as the study was terminated.</population>
      <group_list>
        <group group_id="B1">
          <title>Phase 1 Expansion Cohort A</title>
          <description>Paclitaxel 80mg/m2 weekly days 1, 8, and 15 of a 28-day cycle Ricolinostat dosing as identified as the RP2D combination dose&#xD;
Paclitaxel: Please see arm/group description.&#xD;
Ricolinostat: Please see arm/group description.</description>
        </group>
        <group group_id="B2">
          <title>Phase 1 Expansion Cohort B</title>
          <description>Paclitaxel 70mg/m2 weekly days 1, 8, and 15 of a 28-day cycle Ricolinostat dosing as identified as the RP2D combination dose&#xD;
Paclitaxel: Please see arm/group description.&#xD;
Ricolinostat: Please see arm/group description.</description>
        </group>
        <group group_id="B3">
          <title>Phase 1 Expansion Cohort C</title>
          <description>Paclitaxel 80mg/m2 weekly days 1, 8, and 15 of a 28-day cycle Bevacizumab 10mg/kg days 1 and 15 of a 28-day cycle Ricolinostat dosing as identified as the RP2D combination dose&#xD;
Paclitaxel: Please see arm/group description.&#xD;
Ricolinostat: Please see arm/group description.&#xD;
Bevacizumab: Please see arm/group description.</description>
        </group>
        <group group_id="B4">
          <title>Phase 1 Escalation Cohort</title>
          <description>Ricolinostat with weekly paclitaxel dosed at 80 mg/m2 per week (3 out of 4 weeks).&#xD;
Paclitaxel: Please see arm/group description.&#xD;
Ricolinostat: Please see arm/group description.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="0"/>
            <count group_id="B2" value="0"/>
            <count group_id="B3" value="0"/>
            <count group_id="B4" value="6"/>
            <count group_id="B5" value="6"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Analysis Report on the MTD In The Dose Escalation Portion Of The Study</title>
        <description>Not assessed, the MTD was not reached as the study was terminated.</description>
        <time_frame>2 years</time_frame>
        <population>Data not collected as study was terminated before MTD was reached.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 1 Escalation Cohort</title>
            <description>Ricolinostat with weekly paclitaxel dosed at 80 mg/m2 per week (3 out of 4 weeks).&#xD;
Paclitaxel: Please see arm/group description.&#xD;
Ricolinostat: Please see arm/group description.</description>
          </group>
          <group group_id="O2">
            <title>Phase 1 Expansion Cohort A</title>
            <description>Paclitaxel 80mg/m2 weekly days 1, 8, and 15 of a 28-day cycle Ricolinostat dosing as identified as the RP2D combination dose&#xD;
Paclitaxel: Please see arm/group description.&#xD;
Ricolinostat: Please see arm/group description.</description>
          </group>
          <group group_id="O3">
            <title>Phase 1 Expansion Cohort B</title>
            <description>Paclitaxel 70mg/m2 weekly days 1, 8, and 15 of a 28-day cycle Ricolinostat dosing as identified as the RP2D combination dose&#xD;
Paclitaxel: Please see arm/group description.&#xD;
Ricolinostat: Please see arm/group description.</description>
          </group>
          <group group_id="O4">
            <title>Phase 1 Expansion Cohort C</title>
            <description>Paclitaxel 80mg/m2 weekly days 1, 8, and 15 of a 28-day cycle Bevacizumab 10mg/kg days 1 and 15 of a 28-day cycle Ricolinostat dosing as identified as the RP2D combination dose&#xD;
Paclitaxel: Please see arm/group description.&#xD;
Ricolinostat: Please see arm/group description.&#xD;
Bevacizumab: Please see arm/group description.</description>
          </group>
        </group_list>
        <measure>
          <title>Analysis Report on the MTD In The Dose Escalation Portion Of The Study</title>
          <description>Not assessed, the MTD was not reached as the study was terminated.</description>
          <population>Data not collected as study was terminated before MTD was reached.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Data not collected as study was terminated before MTD was reached</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Best Overall Response Measured From, Start Of Treatment To The End</title>
        <description>This is now the primary outcome measure as the study was terminated prematurely.</description>
        <time_frame>13 months</time_frame>
        <population>Of the six participants, four were evaluable for response by RECIST version 1.1. Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), at least 30% decrease</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 1 Expansion Cohort A</title>
            <description>Paclitaxel 80mg/m2 weekly days 1, 8, and 15 of a 28-day cycle Ricolinostat dosing as identified as the RP2D combination dose&#xD;
Paclitaxel: Please see arm/group description.&#xD;
Ricolinostat: Please see arm/group description.</description>
          </group>
          <group group_id="O2">
            <title>Phase 1 Expansion Cohort B</title>
            <description>Paclitaxel 70mg/m2 weekly days 1, 8, and 15 of a 28-day cycle Ricolinostat dosing as identified as the RP2D combination dose&#xD;
Paclitaxel: Please see arm/group description.&#xD;
Ricolinostat: Please see arm/group description.</description>
          </group>
          <group group_id="O3">
            <title>Phase 1 Expansion Cohort C</title>
            <description>Paclitaxel 80mg/m2 weekly days 1, 8, and 15 of a 28-day cycle Bevacizumab 10mg/kg days 1 and 15 of a 28-day cycle Ricolinostat dosing as identified as the RP2D combination dose&#xD;
Paclitaxel: Please see arm/group description.&#xD;
Ricolinostat: Please see arm/group description.&#xD;
Bevacizumab: Please see arm/group description.</description>
          </group>
          <group group_id="O4">
            <title>Phase 1 Escalation Cohort</title>
            <description>Ricolinostat with weekly paclitaxel dosed at 80 mg/m2 per week (3 out of 4 weeks).&#xD;
Paclitaxel: Please see arm/group description.&#xD;
Ricolinostat: Please see arm/group description.</description>
          </group>
        </group_list>
        <measure>
          <title>Best Overall Response Measured From, Start Of Treatment To The End</title>
          <description>This is now the primary outcome measure as the study was terminated prematurely.</description>
          <population>Of the six participants, four were evaluable for response by RECIST version 1.1. Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), at least 30% decrease</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Partial Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stable Disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peripheral Neurotoxicity Assessed Using TNS by Measuring 5 Categories</title>
        <description>No assessed TNS would only be assessed during escalation which we did not reach as the study was terminated.</description>
        <time_frame>0 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration Of Overall Response, Measured From The Time Measurement Criteria Are Met For PR or CR Until The First Date Recurrent Or Progressive Disease Is Objectively Documented.</title>
        <description>Not assessed, study was terminated.</description>
        <time_frame>2 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression-free Survival (PFS)</title>
        <description>No assessed, study was terminated.</description>
        <time_frame>2 years</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data was collected for 1 year, 1 month.</time_frame>
      <desc>No patients were enrolled in any of the expansion cohorts.</desc>
      <group_list>
        <group group_id="E1">
          <title>Phase 1 Expansion Cohort A</title>
          <description>Paclitaxel 80mg/m2 weekly days 1, 8, and 15 of a 28-day cycle Ricolinostat dosing as identified as the RP2D combination dose&#xD;
Paclitaxel: Please see arm/group description.&#xD;
Ricolinostat: Please see arm/group description.</description>
        </group>
        <group group_id="E2">
          <title>Phase 1 Expansion Cohort B</title>
          <description>Paclitaxel 70mg/m2 weekly days 1, 8, and 15 of a 28-day cycle Ricolinostat dosing as identified as the RP2D combination dose&#xD;
Paclitaxel: Please see arm/group description.&#xD;
Ricolinostat: Please see arm/group description.</description>
        </group>
        <group group_id="E3">
          <title>Phase 1 Expansion Cohort C</title>
          <description>Paclitaxel 80mg/m2 weekly days 1, 8, and 15 of a 28-day cycle Bevacizumab 10mg/kg days 1 and 15 of a 28-day cycle Ricolinostat dosing as identified as the RP2D combination dose&#xD;
Paclitaxel: Please see arm/group description.&#xD;
Ricolinostat: Please see arm/group description.&#xD;
Bevacizumab: Please see arm/group description.</description>
        </group>
        <group group_id="E4">
          <title>Phase 1 Escalation Cohort</title>
          <description>Ricolinostat with weekly paclitaxel dosed at 80 mg/m2 per week (3 out of 4 weeks).&#xD;
Paclitaxel: Please see arm/group description.&#xD;
Ricolinostat: Please see arm/group description.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>syncopal episode</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>localized edema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>neutrophil count decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>anorexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>generalized muscle weakness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>dysgeusia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>alopecia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>nail discoloration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Joyce Liu</name_or_title>
      <organization>Dana-Farber Cancer Insitute</organization>
      <phone>617-632-5269</phone>
      <email>joyce_liu@dfci.harvard.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

